Latest Hydralyte News

Hydralyte LLC recorded its first monthly operating profit in August, while a major cost reset cut its quarterly operating loss to US$66,900. But revenue fell 21.9%, cash narrowed to US$173,400 and the company is seeking up to A$1.4 million through a rights issue.

The Hydration Pharmaceuticals Company (ASX:HPC) has sharply reduced its operating losses, with Hydralyte LLC recording its first monthly EBITDA profit in August. The group remains loss-making overall, but improved margins and a lower cost base are beginning to show in the numbers.

Hydralyte USA secures A$392,000 through a share placement, appoints two new non-executive directors, and implements significant cost reductions following CEO resignation as it targets cash-flow break-even and strategic expansion.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

Hydralyte USA has implemented targeted headcount reductions saving around US$25,000 monthly and completed manufacturing runs to resolve supply shortages, replenishing inventory with key distributors to support near-term sales growth.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

Hydralyte USA has completed its Rights Issue by placing 5 million shortfall shares, raising a total of $608,878 before costs. The move finalizes the company’s recent capital raising efforts under full regulatory compliance.

Hydralyte USA has placed 39.5 million shortfall shares at $0.01 each, boosting total funds raised under its recent Rights Issue to nearly $559,000. The move strengthens the company’s capital position amid ongoing growth efforts.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.